Market Overview

BioDelivery Sciences Announces Upcoming Investor Conference Presentations


RALEIGH, N.C., Aug. 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that Herm Cukier, Chief Executive Officer, will present at the following investor conferences:

  • H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 11:15 AM ET
             Link to webcast:
  • Janney Montgomery Scott Healthcare Conference 2019 on Tuesday, September 10, 2019 at 11:30 AM ET

Replays of the Wells Fargo and H.C. Wainwright conference presentations will be archived on the Company's website and made available for 60 days.


BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, opioid dependence, and opioid-induced constipation.


Bob Yedid
LifeSci Advisors, LLC
(646) 597-6989

Primary Logo

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at